Patent application

The Canadian Intellectual Property Office intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine

Retrieved on: 
Monday, January 24, 2022

STOCKHOLM, Jan. 24, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, 24thJanuary 2022, that the Canadian Intellectual Property Office ("CIPO") has issued a "Notice of Allowance", which means that it intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine.

Key Points: 
  • STOCKHOLM, Jan. 24, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, 24thJanuary 2022, that the Canadian Intellectual Property Office ("CIPO") has issued a "Notice of Allowance", which means that it intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine.
  • The Canadian patent will provide RhoVac's onilcamotide vaccine with broad protection in a key market and significantly strengthens the company's patent portfolio.
  • The Canadian Intellectual Property Office ("CIPO") has communicated its intention to grant RhoVac's Patent Application No.
  • The patent covers RhoVac's onilcamotide cancer vaccine, possible variants of the vaccine and the use of such vaccines in the treatment or prevention of metastatic cancer where RhoC is expressed.

The Canadian Intellectual Property Office intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine

Retrieved on: 
Monday, January 24, 2022

STOCKHOLM, Jan. 24, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, 24thJanuary 2022, that the Canadian Intellectual Property Office ("CIPO") has issued a "Notice of Allowance", which means that it intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine.

Key Points: 
  • STOCKHOLM, Jan. 24, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, 24thJanuary 2022, that the Canadian Intellectual Property Office ("CIPO") has issued a "Notice of Allowance", which means that it intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine.
  • The Canadian patent will provide RhoVac's onilcamotide vaccine with broad protection in a key market and significantly strengthens the company's patent portfolio.
  • The Canadian Intellectual Property Office ("CIPO") has communicated its intention to grant RhoVac's Patent Application No.
  • The patent covers RhoVac's onilcamotide cancer vaccine, possible variants of the vaccine and the use of such vaccines in the treatment or prevention of metastatic cancer where RhoC is expressed.

Treace Announces Grant of U.S. Patent and Allowance of U.S. Patent Application on Bone Positioner Technology for Bunion Correction

Retrieved on: 
Tuesday, November 30, 2021

11,185,359, titled Bone Positioning Guide, and also issued a Notice of Allowance for the Companys pending U.S. Patent Application No.

Key Points: 
  • 11,185,359, titled Bone Positioning Guide, and also issued a Notice of Allowance for the Companys pending U.S. Patent Application No.
  • The granted patent relates generally to techniques, including for use in bunion correction surgery, for moving the first metatarsal with a positioning instrument.
  • The allowed patent application relates generally to techniques for correcting a bunion deformity involving the use of a bone preparation guide and a positioning instrument.
  • The newly granted patent and allowed patent application expand Treaces comprehensive patent coverage on instrumented bunion correction techniques with particular emphasis on metatarsal bone positioning instrumentation, a product category Treace pioneered through its innovative development efforts.

Agtech Global International Inc., Announces its Intention to Change Its Name to Galexxy Holdings Inc.

Retrieved on: 
Wednesday, August 4, 2021

Newport Beach, California, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Agtech Global International Inc., (OTC Pink: AGGL) following its recent acquisition of Galexxy Corporation is pleased to inform the market of its intention to change its corporate name to Galexxy Holdings Inc.

Key Points: 
  • Newport Beach, California, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Agtech Global International Inc., (OTC Pink: AGGL) following its recent acquisition of Galexxy Corporation is pleased to inform the market of its intention to change its corporate name to Galexxy Holdings Inc.
  • This impending name change is consistent with AGGLs plan to realign its operations as a Seed to Sale online consumer products business and build Galexxy as an esteemed consumer brand in the Hemp CBD marketplace.
  • Galexxy has filed a United States provisional patent application to protect its core Virtual Retail Marketing System technology which underpins its marketing and growth strategy, while creating additional revenue opportunities.
  • Galexxy intends to file a Patent Cooperation Treaty patent application prior to the one-year priority to protect the inventive concepts in jurisdictions of business value worldwide.

GBT Filed a Nonprovisional Patent Application - IC Layout Design Rule Automatic Correction

Retrieved on: 
Wednesday, August 4, 2021

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK:GTCH ) ("GBT or the Company), filed a nonprovisional patent application for ICs automatic design rule correction system and method; application #17391292 with the U.S. Patent and Trademark Office (USPTO).

Key Points: 
  • SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK:GTCH ) ("GBT or the Company), filed a nonprovisional patent application for ICs automatic design rule correction system and method; application #17391292 with the U.S. Patent and Trademark Office (USPTO).
  • The patent protects systems and methods for automatic correction of geometrical design rule violations which typically takes vast amount of time to correct manually.
  • A typical process of manual correction of design rule violations may take several hours or even days, per layout block; and significantly, increases the overall design time.
  • IC design firms will benefit designing smaller chips, faster and much cheaper, which will create many new markets and opportunities.

Tauriga Sciences Inc. Reveals its Upcoming In-Person Tradeshow Schedule: White Label World Expo, MJBizCon, and Kosherfest 2021

Retrieved on: 
Tuesday, August 3, 2021

NEW YORK, NY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, has today revealed its upcoming “In-Person” Tradeshow schedule.  The Company will be operating its Corporate Exhibitor Booth at each of these Tradeshows.  Due to the Pandemic - the Company had previously been limited to Virtual Tradeshows, since March 2020.  The Company is both excited and enthusiastic to Showcase its innovative products and product lines to a broad array of Buyers, Distributors, Customers, and Interested Parties.

Key Points: 
  • Description: This is Where the Global Kosher Industry does Business.
  • From Chain Supermarkets to Corner Groceries, Foodservice Establishments to Caterers, Every Kind of Kosher Decision Maker will find Opportunity and Inspiration at Kosherfest 2021.
  • Please visit our corporate website, for additional information, as well as inquiries, athttp://www.tauriga.com
    Complementary to the Companys retail business, is its ongoing Pharmaceutical Development initiative.
  • Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application.The Patent, filed with the U.S.P.T.O.

Notice from the Office of the Secretary - Ontario Securities Commission

Retrieved on: 
Friday, July 30, 2021

TORONTO, July 30, 2021 /CNW/ -The Applicant, Alvin Jones,filed an Amended Application dated July 16, 2021.

Key Points: 

TORONTO, July 30, 2021 /CNW/ -The Applicant, Alvin Jones,filed an Amended Application dated July 16, 2021.
A copy of the Amended Application dated July 16, 2021 is available at www.osc.ca

Global Nanobiotechnology Applications and Markets Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 27, 2021

The "Nanobiotechnology: Applications and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nanobiotechnology: Applications and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • These converging forces result in nanobiotechnology being used in a variety of applications and materials.
  • The purpose of this report is to provide a global, regional and national assessment of the nanobiotechnology application market's potential as well as its existing products, services, future market sizes.
  • This is important because nanobiotechnology markets vary substantially in terms of regional characteristics and depending on the technology in question.

TrippBio receives Notice of Allowance from the U.S. Patent Office for Therapeutic Treatment of COVID-19 Infections

Retrieved on: 
Thursday, July 15, 2021

JACKSONVILLE, Fla., July 15, 2021 /PRNewswire-PRWeb/ --TrippBio, Inc. (TrippBio), a clinical development-stage company developing antiviral treatments with an initial focus on COVID-19, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No.

Key Points: 
  • JACKSONVILLE, Fla., July 15, 2021 /PRNewswire-PRWeb/ --TrippBio, Inc. (TrippBio), a clinical development-stage company developing antiviral treatments with an initial focus on COVID-19, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No.
  • 16/875,487, and the European Patent Office (EPO) has issued a favorable opinion in a counterpart European application.
  • The availability of safe and effective treatment options can reduce the rate of hospitalizations and hopefully the long-term effects of COVID-19."
  • TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance Chair and professor at the University of Georgia.

GeoVax Announces Issuance of Hepatitis B Vaccine Patent

Retrieved on: 
Wednesday, July 7, 2021

11,052,148, entitled Composition and Methods of Generating an Immune Response to Hepatitis B Virus.

Key Points: 
  • 11,052,148, entitled Composition and Methods of Generating an Immune Response to Hepatitis B Virus.
  • The abstract contained in the Companys patent application describes the invention as follows: The compositions and methods are described for generating an immune response to a hepatitis B virus.
  • The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus.
  • We are pleased now to have been notified of the formal patent issuance.